<DOC>
	<DOCNO>NCT02242253</DOCNO>
	<brief_summary>Main Study : To evaluate compare lung function response free combination tiotropium 18 μg ( QD ) + salmeterol 50 μg ( QD BID ) , salmeterol 50 μg BID tiotropium 18 μg QD end 6-week treatment period patient COPD . Sub-Study : Was perform subset patient participate Main Study assess effect four randomise treatment dynamic hyperinflation . Extension Study : To establish whether FEV1 time profile follow combination bronchodilator therapy tiotropium plus salmeterol affect pharmaceutical formulation salmeterol , i.e . MDI Diskus® .</brief_summary>
	<brief_title>Free Combinations Tiotropium Inhalation Powder Capsule + Salmeterol Metered Dose Inhaler , Tiotropium Inhalation Powder Capsule Salmeterol Metered Dose Inhaler Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>1 . All patient must sign informed consent consistent International Conference Harmonization Good Clinical Practice ( ICHGCP ) guideline prior participation trial , include medication washout restriction 2 . All patient must diagnosis chronic obstructive pulmonary disease must meet follow spirometric criterion : Patients must relatively stable , moderate severe airway obstruction FEV1 ≤ 60 % predict normal FEV1 ≤ 70 % FVC ( Visits 1 2 ) 3 . Male female patient 40 year age old 4 . Patients must current exsmokers smoke history 10 packyears ( Patients never smoke cigarette exclude ) 5 . Patients must able perform technically acceptable pulmonary function test must able maintain record ( Patient Daily Diary Card ) study period require protocol 6 . Patients must able inhale medication competent manner HandiHaler® device meter dose inhaler ( MDI ) 1 . Patients significant disease COPD exclude . A significant disease define disease opinion investigator may either put patient risk participation study disease may influence result study patient 's ability participate study 2 . Patients clinically relevant abnormal baseline haematology , blood chemistry , urinalysis , abnormality defines significant disease define exclusion criterion No . 1 3 . Patients recent history ( i.e . six month less ) myocardial infarction 4 . Patients unstable lifethreatening cardiac arrhythmia patient hospitalise event within past year 5 . Patients malignancy patient undergone resection , Radiation therapy chemotherapy within last five year . Patients treat basal cell carcinoma allow 6 . Patients know narrowangle glaucoma 7 . Patients history asthma , allergic rhinitis total blood eosinophil count ≥600 mm3 8 . Patients history lifethreatening pulmonary obstruction , history cystic fibrosis clinically evident bronchiectasis 9 . Patients know active tuberculosis 10 . Patients history and/or active significant alcohol drug abuse . See exclusion criterion No . 1 11 . Patients undergone thoracotomy pulmonary resection . Patients history thoracotomy reason evaluate per exclusion criterion No . 1 12 . Patients complete pulmonary rehabilitation program six week prior Screening Visit ( Visit 1 ) 13 . Patients regularly use daytime oxygen therapy 14 . Patients take investigational drug within one month six half life ( whichever great ) prior Screening Visit ( Visit 1 ) 15 . Patients treat oral betaadrenergics 16 . Patients treat cromolyn sodium nedocromil sodium 17 . Patients treated antihistamine ( H1 receptor antagonist ) , antileukotrienes leukotriene receptor antagonist asthma exclude allergic condition . See exclusion criterion No . 7 18 . Patients use oral corticosteroid medication unstable dos ( i.e. , less six week stable dose ) dose excess equivalent 10 mg prednisone per day 20 mg every day 19 . Patients know hypersensitivity anticholinergic drug , betaadrenergics , lactose component medication delivery system 20 . Pregnant nursing woman woman childbearing potential use medically approve mean contraception previous 3 month ( i.e . oral contraceptive , intrauterine device , diaphragm subdermal implant eg : Norplant® ) 21 . Patients previous participation ( receipt randomise treatment ) study 22 . Patients currently participate another study 23 . The randomisation patient respiratory infection COPD exacerbation six week prior Screening Visit ( Visit 1 ) baseline period postpone . Patients may randomise six week follow recovery infection exacerbation</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>